CG Oncology (CG Oncology) Days Payable : 0.00 (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Days Payable?

CG Oncology's average Accounts Payable for the three months ended in Mar. 2024 was $3.95 Mil. CG Oncology's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.00 Mil.

The historical rank and industry rank for CG Oncology's Days Payable or its related term are showing as below:

CGON's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.28
* Ranked among companies with meaningful Days Payable only.

CG Oncology's Days Payable stayed the same from Dec. 2022 (0.00) to Mar. 2024 (0.00). stayed the same

CG Oncology Days Payable Historical Data

The historical data trend for CG Oncology's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Days Payable Chart

CG Oncology Annual Data

Trend

Dec21

Dec22

Dec23

Days Payable

CG Oncology Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Days Payable	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of CG Oncology's Days Payable

For the Biotechnology subindustry, CG Oncology's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CG Oncology's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CG Oncology's Days Payable distribution charts can be found below:

* The bar in red indicates where CG Oncology's Days Payable falls into.

CG Oncology Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

CG Oncology's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (0.985	+	3.242)	/	2 )	/	0	*	365
=	2.1135					/	0	*	365
=	N/A

CG Oncology's Days Payable for the quarter that ended in Mar. 2024 is calculated as:

	Days Payable (Q: Mar. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2023 )	+	Accounts Payable (Q: Mar. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
=	( (3.242	+	4.658)	/	2 )	/	0	*	365 / 4
=	3.95					/	0	*	365 / 4
=	N/A

CG Oncology Days Payable Related Terms

Thank you for viewing the detailed overview of CG Oncology's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology (CG Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines

From GuruFocus

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

By Marketwired • 04-24-2024